The short answer: yes, with the right selection criteria

Yes — the patella is a recognised anatomical candidate for ChondroFiller injection, provided the damage is focal and the joint's mechanics are stable.

Chondromalacia patella produces precisely the structural deficit that ChondroFiller is designed to address: a localised area of softened or thinning cartilage on the underside of the kneecap, with a defined border and surrounding tissue that remains intact. When cartilage damage fits that pattern, the injectable collagen scaffold has a surface to bond to and a mechanical environment in which it can work.

Physiotherapy, hyaluronic acid, corticosteroid injections, and PRP all have a place in managing chondromalacia. What they share, however, is that they relieve symptoms and may slow early deterioration without repairing the structural lesion itself. ChondroFiller injection is positioned to fill that gap — sitting between conventional injection therapy and surgery on the treatment pathway.

Selection is the operative word. Patients with diffuse or advanced patellofemoral wear, or with uncorrected patellar malalignment, fall outside the indicated window. For those who meet the criteria, though, the kneecap is a well-supported site for this treatment.

Why the patella develops cartilage damage — and why it matters structurally

The posterior surface of the patella carries up to 7 mm of articular cartilage — the thickest found anywhere in the human body. That thickness is not incidental: it reflects the compressive and shear forces the kneecap absorbs with every step, stair, and squat. As the knee flexes, patellofemoral contact pressure rises sharply, and the cartilage takes that load directly.

Chondromalacia patella describes the softening and progressive breakdown of this cartilage layer. The underlying drivers are typically mechanical: weak quadriceps or hip abductors allow the kneecap to track laterally, a high Q-angle concentrates load unevenly, and previous trauma can alter contact patterns permanently. The cartilage responds to abnormal stress by losing its organised collagen architecture — first softening, then fissuring, then thinning.

The clinical problem is that adult articular cartilage has negligible capacity to repair itself. It is avascular and sparsely cellular; once the surface degrades beyond early softening, recovery without intervention is unlikely. ICRS grading classifies Grade III–IV lesions as significant partial to full-thickness loss — the stage at which managing pain alone reaches its functional ceiling. Symptom-directed treatments can reduce discomfort and may slow early deterioration, but they leave the structural deficit intact. It is at this grade that a restorative option, rather than purely palliative care, becomes the relevant clinical question.

How ChondroFiller injection works at the patellofemoral surface

The mechanism is straightforward in concept, even if the biology is precise. ChondroFiller injection is delivered as a liquid — an acellular Type I collagen scaffold — directly into the patellofemoral compartment under ultrasound guidance, as an outpatient procedure. No theatre, no general anaesthetic, and no penetration of the subchondral bone.

Once placed, the collagen transitions from liquid to gel at the defect site, forming a three-dimensional scaffold over the damaged patellar surface. That scaffold functions as a chemotactic matrix: it creates the conditions needed to recruit the patient's own progenitor cells to migrate in from surrounding tissue and synovial fluid, then differentiate into scaffold-supported repair tissue. The process is known as matrix-induced chondrogenesis — ChondroFiller contains no cells of its own; it signals the body to supply them.

This additive, top-down approach differs meaningfully from microfracture, which relies on penetrating the subchondral bone to release marrow cells. That penetration disrupts the bone plate and typically produces fibrocartilage — a mechanically inferior substitute that tends to break down within two to three years. ChondroFiller injection leaves the subchondral plate intact, which matters both for the quality of the repair environment and for preserving future treatment options should they be needed.

The patella's anatomy supports the ultrasound-guided route well. The patellofemoral compartment is accessible for image-guided injection, and the procedure can be completed in a single outpatient visit without the dry-field arthroscopic set-up that surgical techniques require.

ChondroFiller is a CE-marked Class III medical device. It does not currently hold FDA approval, so availability outside Europe remains limited.

Which patients are suitable — and which are not

Beyond lesion grade and localisation, two practical thresholds define the candidacy window. Lesion size should be up to approximately 3 cm² at the patellar surface; Clinical Evaluation Report data allow extension to around 6 cm² in selected cases. The damage must remain focal — once wear becomes diffuse across the patellofemoral surface, or involves the opposing trochlear surface significantly (bipolar disease), the indication moves outside ChondroFiller injection's range. An MRI is needed to characterise lesion boundaries, confirm that surrounding cartilage is healthy, and assess the subchondral bone before a decision is made.

Patients should have trialled conservative care — a structured programme of quadriceps and hip strengthening, and at least one injection-based therapy — without adequate response before ChondroFiller injection is indicated.

The mechanical environment matters as much as the lesion itself. A poorly tracking kneecap concentrates load unevenly across the repair site; if a high Q-angle or patellar malalignment is left uncorrected, the same abnormal force distribution that originally degraded the cartilage will stress the scaffold and impair the repair tissue forming within it. Untreated ligament instability carries the same risk. Where mechanical factors are present, they should be addressed before or alongside the injection to give the scaffold the stable environment it needs for cell ingrowth to take hold over time.

Patients who are not suitable include those with active joint infection, diffuse osteoarthritis spanning the whole patellofemoral compartment, or a disrupted subchondral bone plate from prior marrow-stimulation procedures such as microfracture — which can compromise the scaffold's anchorage and the biological conditions needed for repair.

What the clinical evidence shows — and where the gaps are

The broadest outcome anchor available is the IKDC score: across knee patients treated with ChondroFiller injection, scores improve by approximately 30 points over one year, a finding consistent across manufacturer-sponsored investigations and independent clinical review. MOCART scores — MRI-based assessments of cartilage fill quality — range from 70 to 87, indicating a meaningful structural repair signal rather than symptomatic relief alone. The complaint rate across the ChondroFiller clinical record sits at approximately 0.06%, reflecting a favourable safety profile.

The honest qualification is this: those figures cover knee reporting as a whole. Published clinical trials have not routinely disaggregated outcomes by anatomical compartment, so a patella-specific ChondroFiller IKDC figure does not yet exist in the public literature.

The biological question — whether the patellofemoral compartment responds to injectable regenerative approaches at all — is separately addressed by Zheng et al. (2021), a review of intra-articular mesenchymal stem cell injections for chondromalacia patella. MSC injections and ChondroFiller work by different mechanisms, and that distinction matters. What Zheng et al. established is something more foundational: that the patellofemoral compartment can mount a clinically meaningful biological response to a regenerative injectable, with safety and improved clinical parameters confirmed across the reviewed studies. That is evidence about compartment receptivity, not ChondroFiller-specific patellar efficacy — and it should be read in that light rather than as a direct proxy for ChondroFiller outcomes.

Where ChondroFiller injection sits in the patella treatment pathway

Mapping ChondroFiller injection onto the treatment pathway clarifies the decision most patients face. The four stages for chondromalacia patella run from symptom management (physiotherapy, oral anti-inflammatories) through biologic joint support (hyaluronic acid, PRP, corticosteroid) to structural restoration — and, at the far end for advanced disease, joint replacement. ChondroFiller injection occupies the third stage, the restorative layer, targeting the cartilage defect itself rather than managing pain or lubricating the joint environment. For patients who have worked through the first two stages without adequate improvement, this positioning has a practical implication: the treatment is an outpatient, ultrasound-guided injection, without the surgical staging, theatre requirements, or extended recovery that OATS, MACI, or ACI demand.

In cases of more advanced patellofemoral wear, a combination protocol has been described pairing ChondroFiller (2.3 mL placed at the cartilage surface) with Arthrosamid (6 mL targeting the synovium). The two products serve distinct biological roles — ChondroFiller acts as a regenerative scaffold, supporting progenitor-cell ingrowth; Arthrosamid is a non-regenerative hydrogel that modifies the synovial environment — and should not be treated as interchangeable alternatives. Structured follow-up is part of the longer-term approach: annual MRI to monitor repair-tissue maturation, with the option of top-up injections as part of a preservation programme.

For most patients, the outstanding question at this stage is not whether the patella is anatomically eligible — the mechanistic and selection case has been set out above — but whether their specific lesion size, mechanical profile, and clinical history fall within the indication window. That assessment requires imaging review and a specialist consultation. Liquid Cartilage™ / ChondroFiller injection is available in the UK at the London Cartilage Clinic on Harley Street; details and appointments are at londoncartilage.com.